Publications by authors named "Fe Garcia Reija"
Introduction: A great challenge in nanomedicine, and more specifically in theranostics, is to improve the specificity, selectivity, and targeting of nanomaterials towards target tissues or cells. The topical use of nanomedicines as adjuvants to systemic chemotherapy can significantly improve the survival of patients affected by localized carcinomas, reducing the side effects of traditional drugs and preventing local recurrences.
Methods: Here, we have used the Shiga toxin, to design a safe, high-affinity protein-ligand (ShTxB) to bind the globotriaosylceramide receptor (GB3) that is overexpressed on the surfaces of preneoplastic and malignant cancer cells in the head and neck tumors.
Article Synopsis
- Squamous epithelia in the head and neck experience constant cell turnover and exposure to cancer-causing agents, yet it's unclear how they maintain balance when the cell cycle is disrupted.
- Researchers investigated human keratinocytes from various sites in the head and neck using drugs that induce DNA damage and affect cell division, as well as inhibitors targeting specific kinases.
- The treatments led to DNA damage and issues with cell division, causing the cells to undergo differentiation and polyploidization, ultimately resulting in a loss of their ability to grow indefinitely, suggesting a protective mechanism against cancer.
We report the case of 71-year-old woman with no prior history who had a left maxillary mass for 6 months. Axial Tomography and Nuclear Magnetic Resonance revealed a lesion of 7.7x6.
View Article and Find Full Text PDFBackground: Standard treatment of patients with T4b squamous cell head and neck cancer (T4b-SCHNC) is concomitant chemo-radiotherapy (CT-RT). Recent Phase III trials with Taxane containing induction chemotherapy (IC) suggest that IC could also play a role in this setting. The value of resecting the residual mass after IC and before RT is not yet clear in this context.
View Article and Find Full Text PDFObjectives: We conducted a multicentric randomized phase II trial comparing 5-FU continuous infusion (PF) and cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy (IC) in locally advanced squamous cell head and neck cancer (LA-SCHNC). Primary objective was complete response (CR) to IC and overall survival (OS) was a secondary objective.
Materials And Methods: PF: cisplatin 100 mg/m(2) i.